Pregnancy Outcomes in Patients with Psoriatic Arthritis

Conclusion

The risk of preterm birth and cesarean delivery were increased in pregnant women with PsA, associated with exposure to anti-rheumatic treatment during pregnancy, especially biologic treatments. Because parity influences the risk of preterm birth in women with PsA, special attention to first pregnancies is warranted. Women with PsA should receive individualized monitoring during pregnancy.

For full study details, including source material, refer to the full article.

Excerpted and adapted from:

Remaeus K, Johansson K, Granath F, et al. Pregnancy outcomes in women with psoriatic arthritis in relation to presence and timing of antirheumatic treatment. Arthritis Rheumatol. 2022 Mar;74(3):486–495.

How to minimize the risks of pregnancy for women with SLE

The decision to continue or discontinue immunomodulatory medications during pregnancy is a difficult one for both patients and physicians. On the one hand, when left untreated, rheumatic conditions can cause harm to an unborn child, as well as to the pregnant mother. On the other hand, medications can be harmful to a developing fetus. In…

A treat-to-target approach to managing rheumatoid arthritis can work even in pregnant women

Preconception planning is essential to help women with autoimmune disease have optimal pregnancy outcomes. Unplanned pregnancy can also negatively impact disease course in some patients. Yet many rheumatologic patients of childbearing age do not receive adequate contraception or prepregnancy education and counseling. Rheumatologists must work collaboratively with other healthcare providers to make sure rheumatic patients…

Conclusion

A Better Family Plan

Rheumatologists Should Discuss with Patients Use of Immunomodulatory Agents During Pregnancy

Treat to Target: Rheumatoid Arthritis in Pregnant Patients

Rheumatic Disease Does Not Preclude Pregnancy

Conclusion

Related Articles